CB2202 is a reversible inhibitor of monoamine oxidase-A (MAO-A) in the human brain to modulate key neurotransmitters which regulate different aspects of mood, cognition, and behaviour in human beings. Unlike older inhibitors of MAO-A, our candidate is devoid of potential tyramine induced side effects and provides enhanced tolerability. In addition, current medical opinion is in favour of selective, reversible MAO-A inhibitors as safe treatment in depression1,2. Through direct MAO-A inhibition the drug candidate addresses elevated MAO-A levels in elderly patients, where the larger portion of depression patients are found. By early 2017, CB2202 will be commencing phase II clinical trials in Major Depressive Disorder (MDD) patients.
- Goldberg JF and Thase ME, Monoamine oxidase inhibitors revisited: What you should know. J Clin Psychiatry 74: 189-191 (2013)
- Schulman KI et al., Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27: 789-797 (2013)